An important determinant for the success of every new therapy is the ability to deliver the molecules of interest to the target cells or organ. This selective delivery is even
Erythrocytes as drug delivery systems
The selective delivery of new therapeutic agents to target cells or organs is an important challenge in every clinical approach where peptides, oligonucleotides and/or genes are used. 1 These molecules, although specific, do not easily cross the cell membranes, are usually not very stable in biological fluids and, because of their production costs, should be used in low amounts. The delivery of genes is usually achieved by viral vectors. [2] [3] [4] [5] The delivery of oligonucleotides and peptides is instead mediated by coupling or entrapping these therapeutics to, or in a carrier system that has a significant affinity for one or more cell types within the body. A number of attempts have been made to improve the targeting of drugs by engineering the properties of the carrier system. Examples include the use of Tat, VP22, etc. engineered peptides 6, 7 or the development of drugs conjugated to ligands specific for receptors known to have a selective cell distribution. [8] [9] [10] [11] Although these delivery systems are very interesting, they suffer a number of limitations including the limited number of molecules delivered and potential adverse effects.
Based on these considerations we have developed a cellular drug delivery system which is based on the use of autologous erythrocytes. The carrier system is totally biocompatible, non-immunogenic, with a long life-span in circulation and can be also targeted to macrophages. In fact, human red blood cells have a number of properties that make them useful as drug carriers. Erythrocytes are biodegradable, can circulate for long periods of time (months) and have a large capacity. Moreover, a high percentage of encapsulation can be obtained.
In principle any drug, including peptides, nucleic acids, etc, can potentially be encapsulated into red blood cells. However, several molecules have been shown to leak rapidly through the red cell membrane due to simple diffusion. Other molecules may be toxic to the red cell itself, thus preventing their use as a carrier system. It is interesting to note that red blood cells are 'active' carrier systems, endowed with a number of enzymatic activities that can be conveniently explored to convert an inactive pro-drug into an active drug. This property permits the design of a number of pro-drugs that can be synthesized with charged chemical groups making them non-diffusible or non-toxic. Once these chemical groups have been hydrolyzed by resident red cell enzymes, the pro-drug is converted into an active drug that can diffuse through the red cell membrane and thus released in circulation or at specific sites when red cell targeting is achieved.
In human studies, the use of erythrocytes as a drug delivery system was extensively investigated in vitro and recently validated in vivo. The procedure for the encapsulation of drugs within human erythrocytes is briefly summarized in Figure 1 . This procedure has been modified to be performed in a specially designed apparatus under blood banking conditions. 12 This apparatus, named 'Red Cell Loader' is shown in Figure 2 . At first we have selected dexamethasone-21-phosphate (Dex 21-P) to be encapsulated into human erythrocytes. Dex 21-P is slowly dephosphorylated within erythrocytes to dexamethasone which is then released in circulation. By using the Red Cell Loader we were able to administer 1 to 15 mg of Dex 21-P loaded into erythrocytes to patients with chronic obstructive pulmonary disease (COPD) 13 or cystic fibrosis (CF) (not shown).
In COPD patients, pharmacokinetic analyses have shown that a single administration of drug-loaded erythrocytes (2-4 mg of Dex 21-P) was able to maintain detectable dexamethasone concentrations in blood for up to 7 days (longer time was not evaluated). The continuous release of dexamethasone was paralleled by the suspension of ␤-agonists and oral corticosteroid treatments by all 10 patients enrolled in the clinical trial.
In CF patients, pharmacokinetic analyses were performed for longer periods of time than in COPD patients, and revealed that detectable amounts of plasmatic dexamethasone (0.02-0.05 M) were found 1 month after infusion. Following treatment, no side-effects were observed while general improvement of clinical parameters was obtained (the clinical trial is still in progress).
The administration of non-diffusible pro-drugs by autologous erythrocytes is thus possible, safe and produces benefits to the patients.
Erythrocytes as drug-targeting system
Human erythrocytes, once loaded with the drug of interest, can also be modified to promote autologous immunoglobulin binding and C3b deposition, so that macrophages can recognize and phagocytose the opsonized erythrocytes. By this mechanism the drug encapsulated into the erythrocytes is released within macrophages. 4, 15 By using this system, a number of different compounds can be efficiently delivered. In our laboratory we have tested nucleotide analogues, peptides and modified oligonucleotides. Nucleotide analogues are potent antiviral agents usually administered as nucleoside analogues. These molecules are then phosphorylated into macrophages by cellular or viral enzymes. Unfortunately these enzymes are not always efficient enough to provide a complete protection, thus we reasoned that the delivery of nucleoside analogues in phosphorylated form would have been an advantage. We have proved that this is true both in vitro and in vivo and that new compounds can also be designed, synthesized and delivered using erythrocytes as carriers. 14, [15] [16] [17] [18] Among peptides interesting results were obtained in our laboratory by the delivery of a ubiquitin analogue 19 ( Figure 3 ). This peptide is stable in the erythrocytes and efficiently competes with endogenous ubiquitin in macrophages. Thus, the delivery of peptides is feasible, at least for the ubiquitin analogues.
Finally, we have evaluated the use of erythrocytes for the delivery of modified oligonucleotides. The most common analogues we have encapsulated are the peptide nucleic acids (PNA) analogues with good efficiency (>30%) and acceptable efficacy. The percentage of inhibition of a selected macrophage gene product (iNOs) was in the range of 35 to 40% both in vitro and in vivo suggesting that delivery of modified oligonucleotides can 
ubiquitin K48R into the macrophages (B1). Stimulation of macrophages by lipopolysaccaride (LPS) results in the inhibition of IkB␣ degradation (B2) and abrogation of NF-kB activation. In panel (b) the mechanism of action of ubiquitin K48R is shown. The ubiquitin analogue once added to a polyubiquitin chain prevents its further elongation and the degradation of the target substrate by the 26S proteasome (further details in Ref. 19).
efficiently be performed using erythrocytes (L Chiarantini et al, unpublished results).
Conclusions
Human erythrocytes can provide an efficient way of delivering conventional and new drugs to selected target cells, in particular macrophages. The procedure has been validated by a number of in vitro studies, in animal models and recently in humans.
The method can be easily adapted to deliver different amounts of the compound of interest and with different kinetics. The delivery of recombinant peptides and modified oligonucleotides suggest that the modulation of gene expression is possible by interfering with the activation of specific nuclear factors or with the selected mRNA.
